Poolbeg Pharma (LON:POLB) Given House Stock Rating at Shore Capital

Shore Capital reissued their house stock rating on shares of Poolbeg Pharma (LON:POLB) in a research note published on Thursday,London Stock Exchange reports.

Poolbeg Pharma Stock Down 39.9 %

Poolbeg Pharma stock opened at GBX 4.27 ($0.05) on Thursday. The firm has a fifty day simple moving average of GBX 7.66 and a two-hundred day simple moving average of GBX 10.08. Poolbeg Pharma has a twelve month low of GBX 4.10 ($0.05) and a twelve month high of GBX 15.77 ($0.20). The company has a market capitalization of £21.35 million, a PE ratio of -427.00 and a beta of 2.11.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value.